[1]Song QQ, Xie WY, Tang YJ, et al. Genetic variation in the glucocorticoid pathway involved in interindividual differences in the glucocorticoid treatment[J]. Pharmacogenomics, 2017, 18(3): 293-316.
[2]Danese MD, Katz A, Cetin K, et al. Treatment patterns, survival, and hospitalization in adult patients with acute lymphoblastic leukemia: an observational cohort study using SEER Medicare data[J]. Leuk Lymphoma, 2019, 11: 1-10.
[3]Wermann WK, Gkbuget N. Acute lymphoblastic leukemia-diagnostics, subgroups and therapies [J]. Dtsch Med Wochenschr, 2018, 143(18): 1311-1317.
[4]Pui CH, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia [J]. Nat Rev Drug Discov, 2007, 6(2): 149-165.
[5]Ma L, Fang M, Liang Y, et al. Low expression of glucocorticoid receptor alpha isoform in adult immune thrombocytopenia correlates with glucocorticoid resistance [J]. Ann Hematol, 2013, 92: 953-960.
[6]Zhang L, Hao C, Li J, et al. Bioinformatics methods for identifying differentially expressed genes and signaling pathways in nanosilica stimulated macrophages [J]. Tumor Biol, 2017, 39(6): 1-9.
[7]张轶雯, 楼倩雯, 钟里科, 等. 基于GEO数据库的近端与远端结肠癌特征基因生物信息学研究[J]. 中国临床药理学与治疗学, 2018, 23(4): 422-427.
[8]Guo W, David T, Justin L, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance[J]. Cancer Cell, 2006, 10(4): 331-342.
[9]Maung ZT, Reid MM, Matheson E, et al. Corticosteroid resistance is increased in lymphoblasts from adults compared with children: preliminary results of in vitro drug sensitivity study in adults with acute lymphoblastic leukaemia [J]. Br J Haematol, 1995, 91(1): 93-100.
[10]Clarisse D, Van Wesemael K. Effect of combining glucocorticoids with compound a on glucocorticoid receptor responsiveness in lymphoid malignancies [J]. PLoS One, 2018, 13(5): e0197000.
[11]Habib T, Sadoun A, Nader N, et al. AKT1 has dual actions on the glucocorticoid receptor by cooperating with 14-3-3[J]. Mol Cell Endocrinol, 2017, 5(439): 431-443.
[12]王桂平, 叶云, 杨晓勤, 等. 基于基因表达谱的途径筛选肺腺癌治疗药物[J]. 中国临床药理学与治疗学, 2010, 15(3): 266-272.
[13]Webb MS, Miller AL, Howard TL, et al. Sequential gene regulatory events leading to glucocorticoid-evoked apoptosis of CEM human leukemic cells:interactions of MAPK, MYC and glucocorticoid pathways[J]. Mol Cell Endocrinol, 2018, 15(471): 118-130.
[14]Ramezani S, Shirdel A, Rafatpanah H, et al. Assessment of HTLV-1 proviral load, LAT, BIM, c-FOS and RAD51 gene expression in adult T cell leukemia/lymphoma[J]. Med Microbiol Immunol, 2017, 206(4): 327-335.
[15]Bailey S, Hall AG, Pearson ADJ, et al. The role of AP-1 in glucocorticoid resistance in leukaemia [J]. Leukemia, 2001,15(3): 391-397.
[16]Hayden MS,Ghosh S. NF-kappaB in immunobiology [J]. Cell research, 2011, 21(2): 223-244.
[17]Concetti J, Wilson CL. NFKB1 and cancer: friend or foe [J]? Cells, 2018, 7; 7(9). pii: E133.
[18]Aris IM ,van den Dungen RE, Koudijs MJ, et al. Towards personalized therapy in pediatric acute lymphoblastic leukemia:RAS mutations and prednisolone resistance [J]. Haematologica, 2015, 100(4): e132-136.
[19]Metz HE, Houghton AM. Insulin receptor substrate regulation of phosphoinositide 3-kinase [J]. Clin Cancer Res, 2011, 17(2): 206-211.
[20]Mobaraki RN, Karimi M, Alikarami F, et al. RITA induces apoptosis in p53-null K562 leukemia cells by inhibiting STAT5, Akt, and NF-κB signaling pathways[J]. Anticancer Drugs, 2018, 29(9): 847-853. |